34 patents
Utility
Anti-TIM-3 antibodies and methods of use thereof
12 Dec 23
Antibodies that specifically bind to TIM 3 and antagonize TIM-3 function pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.
Marc van Dijk, Ekaterina Vladimirovna Breous-Nystrom, Nicholas Stuart Wilson, Jeremy Dale Waight, Dennis John Underwood
Filed: 2 Mar 20
Utility
Anti-TIGIT and anti-CD96 antibodies
8 Aug 23
The instant disclosure provides multispecific molecules that specifically bind to CD96 (e.g., human CD96) and/or TIGIT (e.g., human TIGIT) and isolated antibodies that specifically bind to TIGIT (e.g., human TIGIT).
Dhan Sidhartha Chand, Zahra Jawad, Olga Ignatovich, Nicola Anne Ramsay, Spencer Campbell, Beth Wensley, Emmanuel Cyrille Pascal Briend, K. Mark Bushell, Benjamin Maxime Morin, Veronica Franciszka Ilkow
Filed: 10 Aug 22
Utility
Anti-CD73 antibodies and methods of use thereof
4 Jul 23
The instant disclosure provides antibodies that specifically bind to CD73 (e.g., human CD73) and antagonize CD73 function.
Nicholas Stuart Wilson, Jeremy Dale Waight, Shawn Michael Jennings, Olga Ignatovich, Emmanuel Cyrille Pascal Briend, Benjamin Maxime Morin, Oliver Schon, Spencer Campbell
Filed: 8 Mar 19
Utility
Anti-CTLA-4 antibodies and methods of use thereof
2 May 23
The instant disclosure provides antibodies that specifically bind to CTLA-4 (e.g., human CTLA-4) and antagonize CTLA-4 function.
Marc van Dijk, Cornelia Anne Mundt, Gerd Ritter, David Schaer, Jedd David Wolchok, Taha Merghoub, Nicholas Stuart Wilson, David Adam Savitsky, Mark Arthur Findeis, Dennis John Underwood, Jean-Marie Cuillerot, Igor Proscurshim, Olga Shebanova
Filed: 14 Dec 20
Utility
Methods of administering anti-OX40 antibodies
18 Oct 22
The present disclosure provides antibodies that specifically bind to human OX40 receptor (OX40) and compositions comprising such antibodies.
Marc Van Dijk, Ekaterina V. Breous-Nystrom, Volker Seibert, Gerd Ritter, David Schaer, Daniel Hirschhorn-Cymerman, Taha Merghoub, Hao Tang, David A. Savitsky, Jeremy Waight, Nicholas S. Wilson
Filed: 3 Mar 20
Utility
Antibodies and methods of use thereof
20 Sep 22
The present disclosure provides multispecific (e.g., bispecific) antibodies that specifically bind to human GITR and/or human OX40 as well as compositions comprising such antibodies.
Nicholas S. Wilson, Jeremy D. Waight, Gerd Ritter, David Schaer, Daniel Hirschhorn-Cymerman, Taha Merghoub, Ekaterina V. Breous-Nystrom, Volker Seibert, Takemasa Tsuji, Olivier Léger, Dennis J. Underwood, Marc Van Dijk
Filed: 2 Dec 16
Utility
Identification of MHC class I phospho-peptide antigens from breast cancer utilizing SHLA technology and complementary enrichment strategies
16 Aug 22
The present invention describes novel tumor-specific phosphorylated peptides, nucleic acids encoding those peptides, and antibodies generated against said peptides.
Donald F. Hunt, Andrew Norris, Ann Michelle English, Jeffrey Shabanowitz, William H. Hilderbrand, Oriana E. Hawkins
Filed: 2 Mar 20
Utility
Anti-GITR antibodies and methods of use thereof
2 Aug 22
The present disclosure provides antibodies that specifically bind to human glucocorticoid-induced TNFR family related receptor (GITR) and compositions comprising such antibodies.
Ana M. Gonzalez, Nicholas S. Wilson, Dennis J. Underwood, Volker Seibert, Olivier Léger, Marc Van Dijk, Roberta Zappasodi, Taha Merghoub, Jedd David Wolchok, David Schaer, Gerd Ritter, Takemasa Tsuji
Filed: 15 Jan 20
Utility
Anti-OX40 antibodies and anti-GITR antibodies
14 Jun 22
The present disclosure provides antibodies that specifically bind to human OX40 receptor (OX40) and/or human GITR receptor (GITR), including multispecific antibodies that bind, e.g., to OX40 and GITR, and compositions comprising such antibodies.
Nicholas S. Wilson, Jeremy D. Waight, Dennis J. Underwood, Ekaterina V. Breous-Nystrom, Gerd Ritter, David Schaer, Daniel Hirschhorn-Cymerman, Taha Merghoub, Marc Van Dijk
Filed: 9 May 19
Utility
Anti-PD-1 antibodies and methods of use thereof
31 May 22
The instant disclosure provides antibodies that specifically bind to human PD-1 and antagonize PD-1 function.
Marc Van Dijk, Cornelia Anne Mundt, Gerd Ritter, Jedd David Wolchok, Taha Merghoub, Roberta Zappasodi, Rikke Bæk Holmgaard, David Schaer, David Adam Savitsky, Nicholas Stuart Wilson
Filed: 24 Apr 20
Utility
Vectors comprising nucleic acids encoding anti-OX40 antibodies
17 May 22
The present disclosure provides antibodies that specifically bind to human OX40 receptor (OX40) and compositions comprising such antibodies.
Marc Van Dijk, Ekaterina V. Breous-Nystrom, Gerd Ritter, David Schaer, Daniel Hirschhorn-Cymerman, Taha Merghoub, Hao Tang, David A. Savitsky, Nicholas S. Wilson
Filed: 7 Feb 20
Utility
Anti-CTLA-4 antibodies and methods of use thereof
8 Mar 22
The instant disclosure provides antibodies that specifically bind to human CTLA-4 and antagonize CTLA-4 function.
Marc Van Dijk, Cornelia Anne Mundt, Gerd Ritter, David Schaer, Jedd David Wolchok, Taha Merghoub, David Adam Savitsky, Nicholas Stuart Wilson
Filed: 24 Apr 20
Utility
Anti-CD137 antibodies and methods of use thereof
8 Feb 22
The instant disclosure provides antibodies that specifically bind to CD137 (e.g., human CD137) and increases CD137 function.
Yanping Xiao, Nicholas Stuart Wilson, Benjamin Maxime Morin, Mark Arthur Findeis, Cornelia Anne Mundt, Marc van Dijk, Dhan Sidhartha Chand, David Adam Savitsky, Dennis John Underwood, Olga Ignatovich
Filed: 12 Apr 18
Utility
Anti-OX40 antibodies
5 Oct 21
The present disclosure provides antibodies that specifically bind to human OX40 receptor (OX40) and compositions comprising such antibodies.
Marc Van Dijk, Ekaterina V. Breous-Nystrom, Volker Seibert, Gerd Ritter, David Schaer, Daniel Hirschhorn-Cymerman, Taha Merghoub, Hao Tang, David A. Savitsky, Jeremy Waight, Nicholas S. Wilson
Filed: 25 Feb 19
Utility
Anti-CD137 antibodies and methods of use thereof
24 Aug 21
The instant disclosure provides antibodies that specifically bind to CD137 (e.g., human CD137) and increases CD137 function.
Yanping Xiao, Nicholas Stuart Wilson, Benjamin Maxime Morin, Mark Arthur Findeis, Cornelia Anne Mundt, Marc van Dijk, Dhan Sidhartha Chand, David Adam Savitsky, Dennis John Underwood, Olga Ignatovich
Filed: 10 Nov 20
Utility
Heat shock protein-binding peptide compositions and methods of use thereof
20 Jul 21
Provided are polypeptides and compositions comprising novel HSP-binding peptides.
Mark Arthur Findeis, Benjamin Maxime Morin, Bishnu Joshi
Filed: 25 Apr 19
Utility
Anti-ILT4 antibodies and antigen-binding fragments
6 Jul 21
The present invention provides antibodies and antigen-binding fragments thereof that bind to ILT4 (immunoglobulin-like transcript 4) and combinations thereof, e.g., with an anti-PD1 antibody.
Barbara Joyce-Shaikh, Luis A. Zuniga, Milan Blanusa, Andrea Claudia Schuster, Kornelia Schultze
Filed: 5 Apr 18
Utility
Anti-TIGIT antibodies and methods of use thereof
1 Jun 21
The instant disclosure provides antibodies that specifically bind to T-cell immunoreceptor with Ig and ITIM domains (TIGIT) (e.g., human TIGIT) and antagonize TIGIT function.
Dhan Sidhartha Chand, Nicholas Stuart Wilson, Dennis John Underwood, Benjamin Maxime Morin
Filed: 1 May 18
Utility
Anti-CTLA-4 antibodies and methods of use thereof
25 May 21
The instant disclosure provides antibodies that specifically bind to CTLA-4 (e.g., human CTLA-4) and antagonize CTLA-4 function.
Marc van Dijk, Cornelia Anne Mundt, Gerd Ritter, David Schaer, Jedd David Wolchok, Taha Merghoub, Nicholas Stuart Wilson, David Adam Savitsky, Mark Arthur Findeis, Dennis John Underwood, Jean-Marie Cuillerot, Igor Proscurshim, Olga Shebanova
Filed: 7 Dec 17
Utility
Anti-TIM-3 antibodies and methods of use thereof
9 Feb 21
The instant disclosure provides antibodies that specifically bind to TIM-3 (e.g., human TIM-3) and antagonize TIM-3 function.
Marc van Dijk, Ekaterina Vladimirovna Breous-Nystrom, Nicholas Stuart Wilson, Jeremy Dale Waight, Dennis John Underwood
Filed: 2 Mar 20